Ramaswamy-backed pain drug firm to go public via reverse merger
A California-based biotech developing a chronic pain treatment that has been available in Italy for years but lacks US approval is pursuing a reverse merger to list publicly. The company, co-founded by Vivek Ramaswamy, is taking advantage of the growing trend of such deals. The drug's regulatory status in the US remains a key hurdle.
Related stories
Immunology drug developer secures $820M in reverse merger push · Drug development
Redx Pharma pursues reverse merger with Skye to list on Nasdaq · Drug development
Eli Lilly Cracks Down on Illicit Retatrutide Sales · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Chronic pain biotech co-founded by Vivek Ramaswamy joins reverse merger train.” Browse more stories.